Navigation Links
Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for,Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical,Study

SYDNEY, Australia--(BUSINESS WIRE)--Jun 27, 2007 - PrimeCell(TM) Therapeutics LLC (http://www.primecelltherapeutics.com) today announced that it provided research support and pre-clinical studies for a clinical trial to assess the safety, feasibility and efficacy of implanting autologous bone marrow stem cells into spinal cord injury (SCI) patients.

Dr. Luis Geffner presented a preliminary report at the 13th Annual Meeting of the International Society for Cellular Therapy, held here June 24-27. From May 2006 to January 2007, 25 patients with SCI were treated at Luis Vernaza Hospital in Guayaquil, Ecuador. They were treated with autologous bone marrow stem cells - meaning the cells were extracted from the patients' own bone marrow.

Fifteen patients (60 percent) could stand up, ten patients (40 percent) could walk on the parallels with braces, seven (28 percent) could walk without braces, and four (16 percent) could walk with crutches. Patients demonstrated improvements in sensitivity, motility, bladder sensation, even controlling sphincters, erection and ejaculation. No adverse event was observed.

"These preliminary results, while encouraging, must be interpreted cautiously and prudently, and we must continue work examining the benefits of surgically implanted autologous bone marrow stem cells to patients with spinal cord injuries," said Geffner, director of the stem cell program at the Junta de Beneficencia de Guayaquil. He emphasized that this work was done with the help and support of the Junta de Beneficencia, Benemerita Sociedad de Lucha Contra el Cancer (SOLCA), and with the research support and pre-clinical studies performed by stem cell biologist and senior author Francisco Silva and his team at PrimeCell Therapeutics, based in Irvine, Calif.

The study included in vitro (laboratory tests), pre-clinical (animal) and clinical (human) data.

"There is evidence demonstrating signif icant improvement in the quality of life of patients receiving the treatment, including spinal cord regeneration and additional clinical improvements following these stem cell transplants," said Silva, vice president of research and development for PrimeCell Therapeutics. "More research is needed, of course, but this is very encouraging. Our ultimate goal, as always, is not just research - but research that will lead to timely viable therapies."

About PrimeCell(TM) Therapeutics LLC

PrimeCell(TM) Therapeutics LLC, a PrimeGen Biotech company, is devoted exclusively to germ line stem cell reprogramming. Its next generation stem cell - PrimeCell(TM) - is an adult stem cell derived from the germ line and reprogrammed to exhibit pluripotency. Its innovative science and unique approach qualify PrimeCell Therapeutics as one of the preeminent biotechnology firms within the emerging field of regenerative medicine.

Contact

Edge Communications, Inc.
Ken Greenberg, 818-990-5001
ken@edgecommunicationsinc.com
or
Edge Communications, Inc.
Jana Williams, 310-391-9710
janawilliams@dslextreme.com


'"/>




Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... Summary GlobalData,s new report, "Australia Glaucoma ... market data on the Australia Glaucoma Surgery Devices ... US dollars, volume (in units) and average prices ... The report also provides company shares and ...
(Date:12/8/2016)... -- Global Interventional Radiology Market: Scope and Methodology ... market analyzes the current and future prospects of ... summary, including a market snapshot that provides overall ... research is a combination of primary and secondary ... research efforts along with information collected from telephonic ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... ... its 10th anniversary with the grand opening of the Sober College Robert Pfeifer ... spanned two days, December 2-3, and was attended by an overwhelming amount of ...
(Date:12/9/2016)... , ... December 09, 2016 , ... ... at The Pierre Hotel in New York, NY, on December 3rd, to benefit ... and physicians attended the annual event, which raised over $1 million - the ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Pennsylvania Athletic Trainers’ Society ... the summer of 2016. The program was made possible by a Pennsylvania Department ... of Health and Human Services Administration. The broadcast, Use Your Head: Properly ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Institute (WCRI) officially opened registration today for its 33rd Annual Issues & ... MA . , The theme of the conference is “Persistent Challenges and New ...
(Date:12/8/2016)... ... December 08, 2016 , ... Seavest ... Property owned by an affiliate of Seavest, has won a prestigious national healthcare ... Chester County ambulatory care center (ACC) was named “Best New Development, MOBs and ...
Breaking Medicine News(10 mins):